4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide
NVP-BHG712
CAS: 940310-85-0
Molecular Formula: C26H20F3N7O
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide - Names and Identifiers
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide - Physico-chemical Properties
| Molecular Formula | C26H20F3N7O |
| Molar Mass | 503.48 |
| Density | 1.41 |
| Solubility | DMSO: 24.7 mg/mL (40 mM)( < 1 mg/ml refers to the product slightly soluble or insoluble) |
| Appearance | powder |
| Color | white to beige |
| pKa | 13.20±0.70(Predicted) |
| Storage Condition | -20°C |
| MDL | MFCD20272929 |
| Use | NVP-BHG712 |
| Target | c-Abl; C-Raf; c-Src; EphB4; Tie-2 |
| In vitro study | NVP-BHG712 in stably transfected A375 melanoma cells, RTK autophosphorylation was also inhibited in a dose-dependent manner, with EC50 of 25 nM and 4.2 μm for EphB4 and VEGFR2, respectively. |
| In vivo study | NVP-BHG712 the model of angiogenesis induced by oral administration of growth factors at a dose of 3 mg/kg significantly inhibits VEGF-stimulated tissue and angiogenesis by inhibiting EphB4 advancing signal. Furthermore, oral treatment of NVP-BHG712 at a dose of 10 mg/kg/kg effectively reversed VEGF-enhanced tissue formation and blood vessel growth. NVP-BHG712 the mice were treated orally at a dose of 3 mg/kg at a concentration of about 10 μm, and the plasma and lung and liver tissues were treated for a long time for up to 8 hours, resulting in long-term inhibition of EphB4 kinase activity. |
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide - Risk and Safety
| Hazard Symbols | T - Toxic |
| Risk Codes | 25 - Toxic if swallowed |
| Safety Description | 45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
| UN IDs | UN 2811 6.1 / PGIII |
| WGK Germany | 3 |
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.986 ml | 9.931 ml | 19.862 ml |
| 5 mM | 0.397 ml | 1.986 ml | 3.972 ml |
| 10 mM | 0.199 ml | 0.993 ml | 1.986 ml |
| 5 mM | 0.04 ml | 0.199 ml | 0.397 ml |
Last Update：2024-01-02 23:10:35
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide - Animal Experiment
Animal model: VEGF-mediated angiogenesis in vivo is induced in a growth factor implant model in mice.
Last Update：2023-08-16 21:32:38
![4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide](http://res.chembk.com/assets/images/structure/312003.gif)
Supplier List
Spot supply
Product Name: NVP-BHG712 Visit Supplier Webpage Request for quotationCAS: 940310-85-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: NVP-BHG712 Visit Supplier Webpage Request for quotationCAS: 940310-85-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History